METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer

Bookmark and Share
Published: 12 Jun 2020
Views: 129
Prof Mark Awad - Dana Farber Cancer Institute, Boston, USA

Dr Mark Awad speaks to ecancer in an online interview for the ASCO 2020 virtual meeting about METex14 SAs (MET exon 14 skipping alterations) as oncogenic drivers in non-small cell lung cancer.

In his study genomic profiling (CGP) was performed on samples from 60,495 NSCLC patients and 1,393 METex14 SAs were identified in samples.

This may be critical for predicting responses to MET inhibitors and informing rational combination strategies.